{
  "name": "Oncopeptides",
  "slug": "oncopeptides",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T06:12:59Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 1.605, volym 697451",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/oncopeptides/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-13",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Oncopeptides publishes Q1 report 2026",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba63c728cd2dc5f5244354cfbe38d3551&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a640a22fadfde25cdc5f072a65785de3a",
            "date": "2026-05-13",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Interim_Report_Q1_2026_Oncopeptides_AB.pdf",
            "text_chars": 20704,
            "sha256": "26bd05e351472334f0496a128c4ae5d62c86cb43231271c4e277ef9da186d84b",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 20704
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-28",
        "title": "Årsredovisning 2025",
        "original_title": "Oncopeptides publicerar årsredovisningen för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b59e2f33e874bdad672aac3a861f27e35&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad8459a263a0e8ceb0fe0e33b3425b0e7",
            "date": "2026-04-28",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "Arsredovisning_2025_260428_Se.pdf",
            "text_chars": 246195,
            "sha256": "20d4aa61cf83a6cd35f30949b5834bde2b21e8347a3c91a4002177ce23079bba",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 179971
              },
              {
                "number": 2,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 66222
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-19",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Oncopeptides publicerar bokslutskommunikén för 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b39c83566f4cd28de866c50e1fc3b8419&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a009c174c018035acc6195b9c762a26a9",
            "date": "2026-02-19",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Bokslutskommunike_2025.pdf",
            "text_chars": 21313,
            "sha256": "320e8f30e1760f76f8ac269eadfcaa43bbe21db53b07296d0db8c2c81c8c7992",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 21313
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-05",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Oncopeptides publishes Q3 report 2025",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3ed817c232647a7306ed557fd1247346&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac855f4271b5a776cd2a4f4c5c172f305",
            "date": "2025-11-05",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Q3_Report_2025_Oncopeptides_AB.pdf",
            "text_chars": 23475,
            "sha256": "9491cff09c4ba348f5b343f6d21419ffa79d2a2fd1d32733ad72b7a6f0dd7505",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 23475
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-21",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Oncopeptides publicerar rapporten för det andra kvartalet 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3341027f6cbd0253df72b48fce2f79cf&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a10493486bbc8a9087ef3c90e5cb50d5a",
            "date": "2025-08-21",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Q2_Rapport_2025_Oncopeptides_AB.pdf",
            "text_chars": 20247,
            "sha256": "7651de6672d75b6d9d2938f6b81f2a272aa5b1116fbde1293e9e67f97de59237",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 20247
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-15",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Oncopeptides publishes Q1 report 2025",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbee942e56623baa793739e2e2e09f2f6&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ab8595f10b25ed5bbcdb9f37eff2bbeb3",
            "date": "2025-05-15",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "Interim_Report_Q1_2025_Oncopeptides_AB.pdf",
            "text_chars": 20831,
            "sha256": "104d2a975270a2f51b1a1dbd9c25fefccc292e66d0bdf0d80ae2ce31b8efb89c",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 20831
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-28",
        "title": "Årsredovisning 2024",
        "original_title": "Oncopeptides publicerar årsredovisningen för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0ca885f7156672f7cb4a5e25da46b360&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afb04baf8ae0ac2231f36921bc3d4d8d9",
            "date": "2025-04-28",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "Arsredovisning_2024_Oncopeptides_AB.pdf",
            "text_chars": 269301,
            "sha256": "1640dd577580d93bfbd18edbb969556c84b6c456ee499e51a6fcd60cadee3406",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 178236
              },
              {
                "number": 2,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 91063
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-27",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Oncopeptides publicerar bokslutskommunikén för 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7726cd82bed86c978145f2c163d6d9d5&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a620844aaae3c8c829e35bd0c666d17f6",
            "date": "2025-02-27",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Bokslutskommunike_2024_Oncopeptides_AB.pdf",
            "text_chars": 26255,
            "sha256": "24cdb5a54e134e6bd455a87673cd68ea9b8088aaf89f0647c11f697be74c25a8",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 26255
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-07",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Oncopeptides publishes Q3 report 2024",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b88749bc5de7afa92caff80b7ea0317fe&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7cdc25bf84d076ff5cb18e3dcf190981",
            "date": "2024-11-07",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Q3_Report_2024_Oncopeptides_AB.pdf",
            "text_chars": 34486,
            "sha256": "6d8f6d32ed2185c96f327cdb7e3c9abe54ef63a699b1de5730cffea9a446c0ba",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 34486
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-14",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Oncopeptides publicerar rapporten för det andra kvartalet 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be6857c6667761c38a1e3ff2e7906fdf6&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a952a4b468952249f0f72429e317671b9",
            "date": "2024-08-14",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Q2_Rapport_2024_Oncopeptides_AB_publ.pdf",
            "text_chars": 31881,
            "sha256": "2fb9c2eb83d318f884550d60c72ca62540133b468c579722b628dc4d85b0bab4",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 31881
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-30",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Oncopeptides publishes Q1 report 2024",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba64a2f0da65156ccf492300a0568f195&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac36b75da49df57fed7da5dd44741856a",
            "date": "2024-05-30",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf",
            "text_chars": 33589,
            "sha256": "92d5dee1d7fd343fd21517f2f7513483139fba845498473e45ec278dd73160b2",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 33589
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-04-22",
        "title": "Årsredovisning 2023",
        "original_title": "Oncopeptides publicerar årsredovisningen för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba0b3d56c00e10d1b5c1dbb3166308f1e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af6ea68f7a471b0d2bdac0312f245a792",
            "date": "2024-04-22",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "Oncopeptides_AB_publ_Arsredovisning_2023.pdf",
            "text_chars": 278369,
            "sha256": "5927414fddccc6e74bc7495c6be785d134a1885afed9e0eb8c686471e72067f9",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 177330
              },
              {
                "number": 2,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 101037
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-27",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Oncopeptides publicerar bokslutskommunikén för 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6fe088cb2d97713ccf378257a58a514e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a5b34b74e64e0c5e0352da16de120def7",
            "date": "2024-02-27",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "Q4_Bokslutskommunike_2023_20240227.pdf",
            "text_chars": 35422,
            "sha256": "cca77af0ef2c322e6604b48150f366fbfdaea1545b80e6c4b350263685d1f394",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 35422
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-08",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Oncopeptides publishes Q3 report 2023",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b494cb61055f22fb7b563672e017a49ab&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a1cfef8bffada0217bc4e842b5745e094",
            "date": "2023-11-08",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "Interim_Report_Q3_2023.pdf",
            "text_chars": 38994,
            "sha256": "0685206209f958daff1ce1a50b99bfbe38ccf9c3f2a6d3652f6f0dce6be8f5f9",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 38994
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-10",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Oncopeptides publicerar rapporten för andra kvartalet 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bc3b23b1ef100c2d078949d341a6b0417&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a33a1b06248aa2692803318f12b2e541e",
            "date": "2023-08-10",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Oncopeptides_AB_Delarsrapport_Q2_2023.pdf",
            "text_chars": 33250,
            "sha256": "511489b44ac646f8143b032624333f57f51857336a5eb25edf04a985afc0f883",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 33250
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-04",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Oncopeptides publishes Q1 report 2023",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0ab52e703a4b7a0195a3d4299da0e1ef&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a485b398b49174d0cba5f2f87aa103a27",
            "date": "2023-05-04",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "Interim_Report_Q1_2023_ENG_Oncopeptides.pdf",
            "text_chars": 29709,
            "sha256": "e936c0643f451fbbc6ac9a1b48b71c0c4bcdf1f3b5eb2dde58ef2229954b2e00",
            "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 29709
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Oncopeptides",
    "identity": {
      "issuer": "Oncopeptides AB",
      "lei": "549300J9WWQ5CBYQ1M77",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 27,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Oncopeptides",
      "query": "Oncopeptides AB",
      "candidate_count": 347
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T06:12:59Z",
    "insider": {
      "transactions": 30,
      "all_export_rows": 30,
      "acquisitions": 9,
      "disposals": 0,
      "other": 21,
      "acquisition_value_sek": 320658.25,
      "disposal_value_sek": 0,
      "characters": {
        "Förvärv": 9,
        "Teckning": 14,
        "Tilldelning": 7
      }
    },
    "short_selling": {
      "aggregate_percent": 2.45,
      "current_public_positions": 2,
      "historical_changes": 41,
      "current_position_sum_over_0_5": 1.78
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX2304580",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/onco?id=TX2304580"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Oncopeptides",
      "expected_name": "Oncopeptides",
      "match_score": 100.0,
      "slug": "oncopeptides",
      "url": "https://mfn.se/all/a/oncopeptides",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://www.oncopeptides.com/en"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX2304580",
      "asset_class": "SHARES",
      "isin": "SE0009414576",
      "symbol": "ONCO",
      "company": "Oncopeptides",
      "market": null,
      "last_sale_price": "SEK 1.605",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "Oncopeptides AB",
      "lei": "549300J9WWQ5CBYQ1M77",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 27,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Oncopeptides",
      "query": "Oncopeptides AB",
      "candidate_count": 347
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a640a22fadfde25cdc5f072a65785de3a",
      "date": "2026-05-13",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Interim_Report_Q1_2026_Oncopeptides_AB.pdf",
      "text_chars": 20704,
      "sha256": "26bd05e351472334f0496a128c4ae5d62c86cb43231271c4e277ef9da186d84b",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 20704
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad8459a263a0e8ceb0fe0e33b3425b0e7",
      "date": "2026-04-28",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "Arsredovisning_2025_260428_Se.pdf",
      "text_chars": 246195,
      "sha256": "20d4aa61cf83a6cd35f30949b5834bde2b21e8347a3c91a4002177ce23079bba",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 179971
        },
        {
          "number": 2,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 66222
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a009c174c018035acc6195b9c762a26a9",
      "date": "2026-02-19",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Bokslutskommunike_2025.pdf",
      "text_chars": 21313,
      "sha256": "320e8f30e1760f76f8ac269eadfcaa43bbe21db53b07296d0db8c2c81c8c7992",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 21313
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac855f4271b5a776cd2a4f4c5c172f305",
      "date": "2025-11-05",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Q3_Report_2025_Oncopeptides_AB.pdf",
      "text_chars": 23475,
      "sha256": "9491cff09c4ba348f5b343f6d21419ffa79d2a2fd1d32733ad72b7a6f0dd7505",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 23475
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a10493486bbc8a9087ef3c90e5cb50d5a",
      "date": "2025-08-21",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Q2_Rapport_2025_Oncopeptides_AB.pdf",
      "text_chars": 20247,
      "sha256": "7651de6672d75b6d9d2938f6b81f2a272aa5b1116fbde1293e9e67f97de59237",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 20247
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ab8595f10b25ed5bbcdb9f37eff2bbeb3",
      "date": "2025-05-15",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "Interim_Report_Q1_2025_Oncopeptides_AB.pdf",
      "text_chars": 20831,
      "sha256": "104d2a975270a2f51b1a1dbd9c25fefccc292e66d0bdf0d80ae2ce31b8efb89c",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 20831
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afb04baf8ae0ac2231f36921bc3d4d8d9",
      "date": "2025-04-28",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "Arsredovisning_2024_Oncopeptides_AB.pdf",
      "text_chars": 269301,
      "sha256": "1640dd577580d93bfbd18edbb969556c84b6c456ee499e51a6fcd60cadee3406",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 178236
        },
        {
          "number": 2,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 91063
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a620844aaae3c8c829e35bd0c666d17f6",
      "date": "2025-02-27",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Bokslutskommunike_2024_Oncopeptides_AB.pdf",
      "text_chars": 26255,
      "sha256": "24cdb5a54e134e6bd455a87673cd68ea9b8088aaf89f0647c11f697be74c25a8",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 26255
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7cdc25bf84d076ff5cb18e3dcf190981",
      "date": "2024-11-07",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Q3_Report_2024_Oncopeptides_AB.pdf",
      "text_chars": 34486,
      "sha256": "6d8f6d32ed2185c96f327cdb7e3c9abe54ef63a699b1de5730cffea9a446c0ba",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 34486
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a952a4b468952249f0f72429e317671b9",
      "date": "2024-08-14",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Q2_Rapport_2024_Oncopeptides_AB_publ.pdf",
      "text_chars": 31881,
      "sha256": "2fb9c2eb83d318f884550d60c72ca62540133b468c579722b628dc4d85b0bab4",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 31881
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac36b75da49df57fed7da5dd44741856a",
      "date": "2024-05-30",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "INTERIM_REPORT_for_Q1_2024_-_Oncopeptides_AB.pdf",
      "text_chars": 33589,
      "sha256": "92d5dee1d7fd343fd21517f2f7513483139fba845498473e45ec278dd73160b2",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 33589
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af6ea68f7a471b0d2bdac0312f245a792",
      "date": "2024-04-22",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "Oncopeptides_AB_publ_Arsredovisning_2023.pdf",
      "text_chars": 278369,
      "sha256": "5927414fddccc6e74bc7495c6be785d134a1885afed9e0eb8c686471e72067f9",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 177330
        },
        {
          "number": 2,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 101037
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a5b34b74e64e0c5e0352da16de120def7",
      "date": "2024-02-27",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "Q4_Bokslutskommunike_2023_20240227.pdf",
      "text_chars": 35422,
      "sha256": "cca77af0ef2c322e6604b48150f366fbfdaea1545b80e6c4b350263685d1f394",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 35422
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a1cfef8bffada0217bc4e842b5745e094",
      "date": "2023-11-08",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "Interim_Report_Q3_2023.pdf",
      "text_chars": 38994,
      "sha256": "0685206209f958daff1ce1a50b99bfbe38ccf9c3f2a6d3652f6f0dce6be8f5f9",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 38994
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a33a1b06248aa2692803318f12b2e541e",
      "date": "2023-08-10",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Oncopeptides_AB_Delarsrapport_Q2_2023.pdf",
      "text_chars": 33250,
      "sha256": "511489b44ac646f8143b032624333f57f51857336a5eb25edf04a985afc0f883",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 33250
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a485b398b49174d0cba5f2f87aa103a27",
      "date": "2023-05-04",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "Interim_Report_Q1_2023_ENG_Oncopeptides.pdf",
      "text_chars": 29709,
      "sha256": "e936c0643f451fbbc6ac9a1b48b71c0c4bcdf1f3b5eb2dde58ef2229954b2e00",
      "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 29709
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/oncopeptides",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12619,
      "sha256": "36c0518a8d2210243547048c29d6148c63aed257c49c09bd1f3ee5ddac03bde7",
      "url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/oncopeptides/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12619
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/oncopeptides/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/oncopeptides/market/history.json",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/oncopeptides/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/oncopeptides/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/oncopeptides/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/oncopeptides/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/oncopeptides/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/oncopeptides/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/oncopeptides/finansinspektionen",
    "transaction_count": 30,
    "aggregate_short_percent": 2.45,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/oncopeptides/llms.txt",
  "json_url": "/company/oncopeptides/company.json",
  "document_index_url": "/company/oncopeptides/documents.json",
  "absolute_url": "https://spela.port0.org/company/oncopeptides"
}